Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.

The serpin plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of plasminogen activators and a potential therapeutic target in cancer and cardiovascular diseases. Accordingly, formation of a basis for development of specific PAI-1-inactivating agents is of great interest. One possible inactivation mode for PAI-1 is conversion to the inactive, so-called latent state. We have now sc...

Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis

Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients ‎with Coronary Artery Disease

Background: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction with PAI-1 level. Opium addiction i...

The Effects of Regular Aerobic Exercise on the serum levels of Plasminogen Activator Inhibitor-1 and Adiponectin in Obese Girls

Background: The modification of the adipokine levels can be important for the long-term prevention of systemic inflammation related to obesity in children. Objective: The current study aimed to investigate the effects of regular aerobic exercise on the serum levels of plasminogen Activator inhibitor-1(PAI-1) and Adiponectin in obese girls. Methods: This semi experimental research, 14 obese gi...

Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells.

Previous studies have shown that angiotensin II stimulates the synthesis of plasminogen activator inhibitor-1 in cultured vascular cells, which suggests that activation of the renin-angiotensin system may impair fibrinolysis. We have investigated the effects of angiotensin II and of valsartan, a recently developed angiotensin II antagonist that is highly specific and selective for the angiotens...